| Literature DB >> 17156134 |
David C Metz1, John M Inadomi, Colin W Howden, Sander J Veldhuyzen van Zanten, Peter Bytzer.
Abstract
The following pages summarize the proceedings of a symposium held in May 2006 on the emerging role of on-demand therapy for gastroesophageal reflux disease (GERD). Medical therapy for GERD has undergone significant change in recent years with the advent of effective, but expensive, antisecretory agents. On-demand (patient-driven) therapy is attractive to payers and patients, because it appears to be both cost-effective and convenient. Many individuals appear to accept occasional symptomatic breakthrough in exchange for personal control of their disease. On-demand therapy should be distinguished from intermittent therapy, which is either patient- or physician-driven, but which requires intermittent episodes of continuous therapy followed by discontinuation until symptoms recur. Proton pump inhibitors appear to be effective on-demand agents despite theoretical pharmacodynamic limitations for this class of drug. The available data support the use of on-demand therapy for GERD in uninvestigated reflux disease, nonerosive reflux disease, and possibly mild esophagitis as well. On-demand therapy should not be considered for patients with severe esophagitis.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17156134 DOI: 10.1111/j.1572-0241.2006.00998.x
Source DB: PubMed Journal: Am J Gastroenterol ISSN: 0002-9270 Impact factor: 10.864